Oncology and Hematology
113-128 of 790
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Chan Y. Cheah, MBBS
Nicolas Girard, MD
Louise Lim, MD
Jacob Sands, MD
Stephanie McDonald, MSN, FNP-BC, AOCNP
Irene Su, MD, MSCE
Steve Jackson, PharmD
Lyudmila A. Bazhenova, MD
Erica L. Mayer, MD, MPH
Aditya Bardia, MD, MPH, FASCO
Steve Jackson, PharmD
Alexander Spira, MD, PhD, FACP
Aditya Bardia, MD, MPH, FASCO
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
- Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD
